TABLE 3.
Cytokine mRNA induction in PBMC of naïve and vaccinated monkeys during the acute phase p.c.a
| Groupb | IFN-α | IFN-β | Mx | IFN-γ | IL-2 | IL-4 | IL-12 | IL-6 | TNF-α | MIP-1α | MIP-1β | MDCc |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strategy A | ||||||||||||
| Vaccinated-protected | 14/16 (87.5) | 5/16 (31.2) | 10/20 (50.0) | 11/20 (55.0) | 5/20 (25.0) | 6/20 (30.0) | 12/20 (60.0) | 11/20 (55.0) | 11/20 (55.0) | 11/20 (55.0) | 12/20 (60.0) | 11/20 (55.0) |
| Vaccinated-unprotected | 3/10 (30.0) | 4/10 (40.0) | 2/10 (20.0) | 6/11 (54.5) | 4/11 (36.4) | 3/11 (27.3) | 7/11 (63.6) | 5/11 (45.5) | 6/11 (54.5) | 7/11 (63.6) | 5/11 (45.5) | 5/11 (45.5) |
| Vaccine-naive | 4/10 (40.0) | 2/10 (20.0) | 10/12 (83.3) | 2/12 (16.7) | 1/12 (8.3) | 2/12 (16.7) | 8/12 (66.6) | 11/12 (91.7) | 10/12 (83.3) | 10/12 (83.3) | 7/12 (58.3) | 8/12 (66.6) |
| Strategy B | ||||||||||||
| Vaccinated-protected | 11/16 (68.8) | 4/16 (25.0) | 2/20 (10.0) | 5/20 (25.0) | 14/20 (70.0) | 3/20 (15.0) | 9/20 (45.0) | 14/20 (70.0) | 16/20 (80.0) | 12/20 (60.0) | 12/20 (60.0) | 11/20 (55.0) |
| Vaccinated-unprotected | 7/10 (70.0) | 1/10 (10.0) | 6/11 (54.5) | 3/11 (27.3) | 9/11 (81.8) | 1/11 (9.1) | 6/11 (54.5) | 10/11 (90.9) | 9/11 (81.8) | 4/11 (36.4) | 7/11 (63.6) | 7/11 (63.6) |
| Vaccine-naive | 8/12 (66.6) | 3/12 (25.0) | 11/15 (73.3) | 2/15 (13.3) | 8/15 (53.3) | 4/15 (26.7) | 9/15 (60.0) | 12/15 (80.0) | 13/15 (86.7) | 11/15 (73.3) | 9/15 (60.0) | 11/15 (73.3) |
a
Number of monkeys with increased cytokine mRNA levels/total monkeys per group tested (percentage).
b
Strategy A, increase versus prechallenge mRNA levels; strategy B, increase versus PBMC mRNA levels of uninfected monkeys.
c
MDC, macrophage-derived chemokine.